Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Queensland Health
Novartis
Julphar
Daiichi Sankyo
Accenture
Harvard Business School
Medtronic
Cerilliant
Baxter

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,173,854

« Back to Dashboard

Which drugs does patent 9,173,854 protect, and when does it expire?

Patent 9,173,854 protects ZORVOLEX and is included in one NDA.

This patent has thirty-nine patent family members in twenty-two countries.
Summary for Patent: 9,173,854
Title:Formulation of diclofenac
Abstract: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
Inventor(s): Dodd; Aaron (Centennial Park, AU), Meiser; Felix (Mount Claremont, AU), Norret; Marck (Darlington, AU), Russell; Adrian (Rivervale, AU), Bosch; H William (Bryn Mawr, PA)
Assignee: iCeutica Pty Ltd. (Philadelphia, PA)
Application Number:14/621,863
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,173,854

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Iroko Pharms Llc ZORVOLEX diclofenac CAPSULE;ORAL 204592-001 Oct 18, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Iroko Pharms Llc ZORVOLEX diclofenac CAPSULE;ORAL 204592-002 Oct 18, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,173,854

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2009901748Apr 24, 2009

Non-Orange Book US Patents Family Members for Patent 9,173,854

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,679,544 Formulation of diclofenac ➤ Sign Up
9,017,721 Formulation of diclofenac ➤ Sign Up
9,180,095 Formulation of diclofenac ➤ Sign Up
9,186,328 Formulation of diclofenac ➤ Sign Up
9,180,096 Formulation of diclofenac ➤ Sign Up
8,735,450 Formulation of diclofenac ➤ Sign Up
8,999,387 Formulation of diclofenac ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,173,854

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 106232 ➤ Sign Up
Tunisia 2011000543 ➤ Sign Up
Singapore 10201401700X ➤ Sign Up
Singapore 175314 ➤ Sign Up
Philippines 12015500301 ➤ Sign Up
New Zealand 710383 ➤ Sign Up
New Zealand 620887 ➤ Sign Up
New Zealand 595987 ➤ Sign Up
Mexico 347290 ➤ Sign Up
Mexico 337619 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Covington
Mallinckrodt
Merck
UBS
Johnson and Johnson
QuintilesIMS
Federal Trade Commission
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot